Trials / Completed
CompletedNCT00684619
506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)
Phase II-Study With Nelarabine in Patients With Refractory Oder Relapsed T- ALL or T-lymphoblastic Lymphoma (Amend.7)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Goethe University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Nelarabine is effective in the treatment of patients with T-ALL/NHL in order to achieve a complete remission followed by an early stem cell transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nelarabine | 1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5 |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-05-26
- Last updated
- 2022-08-18
Locations
11 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00684619. Inclusion in this directory is not an endorsement.